Simultaneous inhibition of the IL-6/IL-8 signaling network with tocilizumab, a monoclonal anti-IL-6 receptor-alpha (IL-6Rα, hereafter denoted IL-6R) antibody primarily used to treat rheumatoid arthritis [13], and reparixin, a small molecule allosteric inhibitor of the IL-8 receptor (IL-8R) that recently completed phase II clinical trials against breast cancer [14], was found to decrease in vitro cell migration and significantly decrease in vivo metastasis without affecting rates of tumor growth [12,15]. Here, IL6R is linked to neoplasm.